Internationally recognized leaders in the field, PCCTC investigators come from the nation’s top academic medical centers where they are actively engaged in innovative, multidisciplinary prostate cancer research. Leveraging their unique insights into the underlying biology of the disease, our investigators developed the universally adopted clinical states model of prostate cancer and initiated one of the first efforts in oncology to prospectively validate endpoints proposed in definitive phase III trials, PCWG2. The individual research objectives of our investigators are well represented in our clinical trial portfolio and unified by our translational, team-based approach to drug and biomarker development.
Principal Investigators Lorelei Mucci, ScD, MPH (Harvard T.H. Chan School of Public Health...Learn More
New technology provides a major step forward in diagnosing and treating prostate cancer.Learn More
A new manuscript published in JCO Global Oncology describes the PCCTC managed IRONMAN Regi...Learn More
More than 40,000 oncology professionals from around the world will convene at the annual A...Learn More
NORTH BILLERICA, MA, January 27, 2022 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus...Learn More